<DOC>
	<DOCNO>NCT01519011</DOCNO>
	<brief_summary>The primary purpose study evaluate pharmacokinetics oral azacitidine administer daily two 150-mg tablet , include effect food , evaluate bioavailability oral azacitidine 300-mg administer two 150-mg tablet relative three 100-mg tablet .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics , Food Effect , Safety Efficacy Oral Azacitidine</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age 18 year old time signing informed consent document Diagnosis Myelodysplastic Syndromes , Chronic Myelomonocytic Leukemia Acute Myeloid Leukemia Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 At least 3 month life expectancy Adequate organ function , define : Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 time ULN ; Serum creatinine ≤ 1.5 time ULN ; Serum bicarbonate ≥ 20 mEq/L Females childbearing potential ( FCBP ) must : Agree use least two effective contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) throughout study , 3 month follow last dose oral azacitidine ; Have negative serum urine pregnancy test ( investigator 's discretion ; sensitivity least 25 mIU/mL ) screening ; Have negative serum urine pregnancy test ( investigator 's discretion ; sensitivity least 25 mIU/mL ) within 72 hour prior Day 1 pharmacokinetic ( PK ) phase ( note screening pregnancy test use test prior Day 1 PK phase perform within 72 hour timeframe ) . Males partner FCBP must agree partner use least two effective contraceptive method throughout study avoid father child 3 month follow date last oral azacitidine dose Understand voluntarily sign informed consent document prior start study related assessments/procedures Able adhere study visit schedule protocol requirement Suspected proven acute promyelocytic leukemia base morphology , immunophenotype , molecular assay , karyotype Previous treatment azacitidine demethylating agent within 21 day prior start study therapy ongoing adverse event previous treatment , regardless time period Anticancer therapy ( standard investigational ) within 21 day prior start study therapy ongoing adverse event previous treatment , regardless time period Use proton pump inhibitor agent may affect gastric acid level within 28 day prior study therapy ( applicable Part II PK phase ) Concurrent use erythropoiesisstimulating agent ( ESAs ) red blood cell hematopoietic growth factor , except subject stable dose least 4 week ( 28 day ) prior start study therapy Concurrent use ironchelating agent , except subject stable dose least 8 week ( 56 day ) prior start study therapy Concurrent corticosteroid use , except medical condition Myelodysplastic Syndrome provide subject stable decrease dose ≥ 1 week prior start study therapy Pregnant lactating female Any know suspected hypersensitivity azacitidine mannitol ingredient use manufacture oral azacitidine ( see azacitidine IB ) Uncontrolled systemic fungal , bacterial , viral infection ( define ongoing signs/symptoms related infection without improvement despite appropriate antibiotic treatment ) Active viral infection know human immunodeficiency virus ( HIV ) viral hepatitis type B C Presence gastrointestinal disease , malignant hepatic tumor , condition know interfere absorption , distribution , metabolism , excretion drug Current congestive heart failure ( New York Heart Association Class IIIIV Appendix G ) , unstable angina angina require surgical medical intervention within 6 month prior start study therapy , myocardial infarct within 6 month prior start study therapy , uncontrolled cardiac arrhythmia ( define arrhythmia symptomatic require treatment asymptomatic sustain ventricular tachycardia ) . Subjects control atrial fibrillation asymptomatic eligible Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study Any condition confounds ability interpret data study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>MDS</keyword>
	<keyword>Chronic Myelomonocytic Leukemia</keyword>
	<keyword>CMML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Vidaza</keyword>
	<keyword>oral azacitidine</keyword>
	<keyword>aza</keyword>
	<keyword>oral aza</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>hematology</keyword>
	<keyword>myeloid disease</keyword>
	<keyword>PK</keyword>
</DOC>